Roberto Iezzi1, Maurizio Pompili2, Michele Fabio La Torre3, Maria Chiara Campanale2, Martina Montagna2, Antonio Saviano2, Valentina Cesario2, Massimo Siciliano2, Eleonora Annicchiarico2, Salvatore Agnes4, Felice Giuliante5, Antonio Grieco2, Gian Lodovico Rapaccini2, Anna Maria De Gaetano3, Antonio Gasbarrini2, Lorenzo Bonomo3. 1. Department of Bioimaging and Radiological Sciences, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, Rome, Italy; Division of Medical Oncology, "A. Gemelli" Hospital - Catholic University, Rome, Italy. Electronic address: iezzir@virgilio.it. 2. Department of Internal Medicine, "A. Gemelli" Hospital - Catholic University, Rome, Italy; Division of Medical Oncology, "A. Gemelli" Hospital - Catholic University, Rome, Italy. 3. Department of Bioimaging and Radiological Sciences, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, Rome, Italy; Division of Medical Oncology, "A. Gemelli" Hospital - Catholic University, Rome, Italy. 4. Department of Surgery, Division of Organ Transplantation, "A. Gemelli" Hospital - Catholic University, Rome, Italy; Division of Medical Oncology, "A. Gemelli" Hospital - Catholic University, Rome, Italy. 5. Department of Surgery, Hepatobiliary Surgery Unit, "A. Gemelli" Hospital - Catholic University, Rome, Italy; Division of Medical Oncology, "A. Gemelli" Hospital - Catholic University, Rome, Italy.
Abstract
BACKGROUND: Our aim was to evaluate the effectiveness of the single-step combined therapy with radiofrequency ablation and drug-eluting beads transarterial chemoembolization in single hepatocellular carcinoma (HCC) larger than 3cm. Secondary aim was to compare the results with those obtained in a matched population treated with drug-eluting beads transarterial chemoembolization alone. METHODS: 40 consecutive cirrhotic patients with single HCC were prospectively enrolled and treated. Twenty-three patients had tumours between 3 and 5cm (Group A), and 17 larger than 5cm (Group B). Twenty cirrhotic patients with single HCC treated only with chemoembolization formed the control group. RESULTS: Complete response at 1 month was achieved in 32/40 tumours (80%). During follow-up, complete response was maintained in 25 patients (25/40, 62.5%), and this rate was higher in Group A (69.6% vs 53%, p=0.008). The group treated with combined therapy showed a significantly lower 2-year recurrence (48.1% vs 78.2%, p<0.001) and significantly higher survival (91.1% vs 60.6%, p=0.004) than the group treated with chemoembolization alone. CONCLUSIONS: Balloon-occluded-radiofrequency ablation plus drug-eluting beads transarterial chemoembolization is an effective treatment of HCC larger than 3cm not amenable to surgical resection, providing better results than transarterial chemoembolization alone. The best results are achieved in tumours up to 5cm.
BACKGROUND: Our aim was to evaluate the effectiveness of the single-step combined therapy with radiofrequency ablation and drug-eluting beads transarterial chemoembolization in single hepatocellular carcinoma (HCC) larger than 3cm. Secondary aim was to compare the results with those obtained in a matched population treated with drug-eluting beads transarterial chemoembolization alone. METHODS: 40 consecutive cirrhotic patients with single HCC were prospectively enrolled and treated. Twenty-three patients had tumours between 3 and 5cm (Group A), and 17 larger than 5cm (Group B). Twenty cirrhotic patients with single HCC treated only with chemoembolization formed the control group. RESULTS: Complete response at 1 month was achieved in 32/40 tumours (80%). During follow-up, complete response was maintained in 25 patients (25/40, 62.5%), and this rate was higher in Group A (69.6% vs 53%, p=0.008). The group treated with combined therapy showed a significantly lower 2-year recurrence (48.1% vs 78.2%, p<0.001) and significantly higher survival (91.1% vs 60.6%, p=0.004) than the group treated with chemoembolization alone. CONCLUSIONS: Balloon-occluded-radiofrequency ablation plus drug-eluting beads transarterial chemoembolization is an effective treatment of HCC larger than 3cm not amenable to surgical resection, providing better results than transarterial chemoembolization alone. The best results are achieved in tumours up to 5cm.
Authors: Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi Journal: Saudi J Gastroenterol Date: 2020-10 Impact factor: 2.485
Authors: Olumide B Gbolahan; Michael A Schacht; Eric W Beckley; Thomas P LaRoche; Bert H O'Neil; Maximilian Pyko Journal: J Gastrointest Oncol Date: 2017-04
Authors: Lei Chen; Yanqiao Ren; Tao Sun; Yanyan Cao; Liangliang Yan; Weihua Zhang; Tao Ouyang; Chuansheng Zheng Journal: Cancer Med Date: 2021-05-07 Impact factor: 4.452